Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

ABSTRACT: The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

DISEASE(S): Colorectal Neoplasms,Colorectal Cancer Metastatic

PROVIDER: 2177942 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR